Order results by:
| Issue | Title | |
| Vol 10, No 3 (2014) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... Adequate primary and secondary prevention of thromboembolic complications is one of the main goals ..." | ||
| Vol 11, No 6 (2015) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... Adequate primary and secondary prevention of thromboembolic complications is one of the main goals ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..." | ||
| Vol 15, No 4 (2019) | Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..." | ||
| Vol 8, No 3 (2012) | RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... -salicylic acid, warfarin). Efficacy and safety of rivaroxaban is considered on the basis of the results ..." | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| "... Data on the problem of thromboembolic complications in non-valvular atrial fibrillation ..." | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| "... with atrial fibrillation: those who have high bleeding and high thromboembolic risk and elderly. The focus ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... of care warfarin and aspirin, novel oral anticoagulants rivaroxaban and dabigatran. At the same time ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| "... of them oral anticoagulants were used mainly from the group of vitamin K antagonists, most often warfarin ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... on rivaroxaban has changed — instead of "use with caution", as stated in the previous document from 2019 ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| "... and systemic thromboembolism. For patients that were treated by warfarin international normalization ratio (INR ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... warfarin, while only 11.8% had adequate INR control after one year of follow-up. Rivaroxaban was prescribed ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| "... and CKD, in addition to increase in frequency of strokes and the thromboembolic events, also the frequency ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... stroke. The risk of thromboembolic complications increases significantly when performing for electrical ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... .g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... " of the OAC is warfarin, which has proved effectiveness in all categories of patients with AF. A whole group ..." | ||
| Vol 14, No 5 (2018) | Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA | Abstract similar documents |
| Bayer Company Press Release | ||
| "... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..." | ||
| Vol 17, No 2 (2021) | The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation | Abstract similar documents |
| I. A. Zolotovskaya, V. D. Sabanova, I. L. Davydkin | ||
| "... to the search query “Atrial fibrillation, effectiveness and safety of rivaroxaban, warfarin, comorbidity, atrial ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... in the frequency of myocardial infarction between any of the doses of dabigatran and warfarin, and the risk ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... Background. For prevention of thromboembolic events in patients with non-valvular atrial ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... ,3%) patients received vitamin K antagonist (warfarin). The international normalized ratio in the target range ..." | ||
| Vol 11, No 2 (2015) | ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY | Abstract PDF (Eng) similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina | ||
| "... in patients at high risk of thromboembolic events (TEE) and to evaluate clinical characteristics ..." | ||
| Vol 21, No 3 (2025) | Rivaroxaban in stroke prevention in patients with non-valvular atrial fibrillation: what facts are important for the clinician? | Abstract similar documents |
| I. S. Yavelov | ||
| "... trial ROCKET AF, in patients with non-valvular AF, rivaroxaban is at least as effective as warfarin ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... with persistent nonvalvular atrial fibrillation receiving warfarin and direct oral anticoagulants (DOAC ..." | ||
| Vol 17, No 6 (2021) | Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020 | Abstract similar documents |
| A. S. Gerasimenko, O. V. Shatalova, V. S. Gorbatenko, V. I. Petrov | ||
| "... .001), decreased the frequency of administration of warfarin from 71,9% to 18,3% (р<0.001). The frequency of use ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 6, No 4 (2010) | ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS | Abstract similar documents |
| A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov | ||
| "... Appropriate use of warfarin is not in routine clinical practice despite convincing data ..." | ||
| Vol 13, No 5 (2017) | ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT | Abstract similar documents |
| S. G. Kanorskii | ||
| "... of anticoagulant therapy include vitamin K antagonists, such as warfarin, whose benefits are long established ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... % compared with warfarin in the patients aged 75 years and older. The safety of rivaroxaban has been ..." | ||
| Vol 13, No 2 (2017) | RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY | Abstract similar documents |
| . Editorial | ||
| "... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..." | ||
| Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
| N. M. Vorobyeva, O. N. kacheva | ||
| "... The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... .6%) and dabigatran (17.3%) and warfarin (19.4%) were prescribed almost twice as rarely as rivaroxaban ..." | ||
| Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
| S. G. Kanorskii | ||
| "... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 8, No 4 (2012) | WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE | Abstract similar documents |
| E. N. Dankovtseva, S. L. Arkhipov, D. A. Zateyshchikov | ||
| "... Analysis of the current literature data on the use of warfarin in patients with cardioembolic ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... , but in the study took warfarin, demonstrated significantly greater number of thromboembolic complications ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| "... ) are highlighted. The main statements of current Russian and international guidelines about thromboembolic events ..." | ||
| Vol 15, No 4 (2019) | Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko | ||
| "... oral anticoagulants for the prevention of thromboembolic complications in patients with atrial ..." | ||
| Vol 16, No 2 (2020) | Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function | Abstract similar documents |
| N. V. Drobotya, E. Sh. Guseynova, A. A. Pirozhenko | ||
| "... comprehensively. Along with the prevention of thromboembolic complications, it is necessary that the selected ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| "... with increased risk of stroke and thromboembolic complications. Oral anticoagulation for stroke prevention ..." | ||
| Vol 7, No 4 (2011) | LEFT VENTRICULAR CLOT LYSIS DUE TO COMBINED ANTICOAGULANT THERAPY WITH WARFARIN AND FRAXIPARINE IN PATIENT WITH DILATED CARDIOMYOPATHY AND CHRONIC HEART FAILURE. THE CLINICAL CASE | Abstract similar documents |
| O. V. Uskova, K. O. Sobolev, G. E. Gendlin, A. V. Melekhov | ||
| "... anticoagulant therapy with warfarin and fraxiparine in patient with dilated cardiomyopathy, congestive heart ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... and systemic thromboembolic (STE) complications as warfarin, although DOACs were associated with less risk ..." | ||
| Vol 17, No 6 (2021) | Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation | Abstract similar documents |
| T. V. Pavlova | ||
| "... kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 15, No 1 (2019) | Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City | Abstract similar documents |
| A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich | ||
| "... with the risk of thromboembolic complications, and also to study the dynamics of the frequency of administration ..." | ||
| Vol 14, No 1 (2018) | THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES | Abstract similar documents |
| M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov | ||
| "... in patients with atrial fibrillation (AF) receiving anticoagulant therapy with warfarin. Material and methods ..." | ||
| Vol 7, No 5 (2011) | ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva | ||
| "... Aim. To analyze the structure of expenses associated with warfarin dose adjustment ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... compared with patients of warfarin group. Mutations in CYP2C9 gene were detected in 32.9%, VKORC1 – in 68 ..." | ||
| Vol 7, No 1 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... fibrillation. Factors of warfarin therapy efficacy, as well as the possibility of new antithrombotic drugs ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 15, No 5 (2019) | Clinical Case: Atypical Warfarin-induced Skin Necrosis | Abstract similar documents |
| T. V. Kondratieva, L. V. Popova, S. S. Karachev, A. S. Lishuta, M. Z. Kanevskaya | ||
| "... Warfarin-induced skin necrosis (WISN) is a rare complication of antivitamin K therapy, which occurs ..." | ||
| Vol 16, No 1 (2020) | Decrease in Efficacy of Warfarin as a Result of Drug-Drug Interaction (Case Report) | Abstract similar documents |
| N. T. Vatutin, G. G. Taradin, G. A. Ignatenko, E. S. Gasendich, A. V. Harchenko, I. B. Povaljaeva | ||
| "... considering a frequent administration of several drugs having different drug-drug interactions. Warfarin ..." | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| "... and quality of life of the patient. Anticoagulants, widely used in the treatment of thromboembolic ..." | ||
| Vol 5, No 3 (2009) | SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS | Abstract similar documents |
| E. S. Kropacheva | ||
| "... The safety of anticoagulant therapy is discussed. Warfarin position in prevention of thrombotic ..." | ||
| Vol 6, No 5 (2010) | THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY | Abstract similar documents |
| T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva | ||
| "... in the perioperative continuation or termination of warfarin therapy is shown. Potential of the local hemostatic agents ..." | ||
| Vol 8, No 2 (2012) | QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL | Abstract similar documents |
| E. L. Artanova, L. E. Kon'shina, I. M. Sokolov, Y. G. Shvarts | ||
| "... with warfarin after leaving the international clinical trial. Material and Methods. Patients with AF who were ..." | ||
| Vol 10, No 2 (2014) | ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Maslakov | ||
| "... . Acetylsalicylic acid was prescribed to 0.7% of cases (n=2), warfarin – to 5% (n=12). High risk of thromboembolic ..." | ||
| Vol 15, No 4 (2019) | The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries) | Abstract similar documents |
| M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov | ||
| "... (1335 from 3169 patients; age 69.1±10.4 years, 43% men), including warfarin (817 patients; 26%) and non ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most favorable ..." | ||
| Vol 14, No 6 (2018) | Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared ..." | ||
| Vol 14, No 5 (2018) | Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report) | Abstract similar documents |
| G. S. Krasnov, I. V. Kazancev | ||
| "... . As a result of analysis, it was described two drug interactions led to minor bleeding: warfarin ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... .9%) – pernanent. Results. While assessing the risk of thromboembolic complications on the CHA2DS2-VASc scale ..." | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| "... and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented. Large ..." | ||
| Vol 12, No 1 (2016) | Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of rivaroxaban together ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF ..." | ||
| Vol 7, No 2 (2011) | PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE? | Abstract similar documents |
| I. V. Zotova, D. A. Zateyshchikov | ||
| Vol 7, No 4 (2011) | SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS | Abstract similar documents |
| E. L. Artanova, E. V. Saleeva, I. M. Sokolov, Y. G. Shvarts | ||
| "... Aim. To study the relations of clinical characteristics and individual warfarin dose titration ..." | ||
| Vol 16, No 3 (2020) | Thrombosis of Prosthetic Cardiac Valve: Difficulties of Diagnostics on the Example of a Clinical Case with Lethal Outcome | Abstract similar documents |
| A. A. Novoselova, S. S. Yakushin | ||
| "... with the installation of mechanical prosthesis into the aortal position and further warfarin medication, with absence ..." | ||
| Vol 17, No 2 (2021) | Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage | Abstract similar documents |
| A. S. Gerasimenko, V. S. Gorbatenko, O. V. Shatalova, V. I. Petrov | ||
| Vol 8, No 5 (2012) | RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE | Abstract similar documents |
| I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman | ||
| "... fibrillation (AF) with the risk level of thromboembolic complications (TEC), calculated with the СHADS2 and CHA ..." | ||
| Vol 12, No 3 (2016) | THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT | Abstract PDF (Eng) similar documents |
| S. R. Gilyarevskiy | ||
| "... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation ..." | ||
| Vol 19, No 1 (2023) | Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... safety of rivaroxaban in patients over 80 years of age, with a high risk of bleeding ..." | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... was previously demonstrated in ARISTOTLE trial. On the contrary, rivaroxaban was associated with the most ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 16, No 3 (2020) | Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics? | Abstract similar documents |
| S. G. Kanorskii | ||
| "... of rivaroxaban and aspirin in high-risk groups, the rate of adverse events, including cardiovascular death ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban ..." | ||
| Vol 14, No 6 (2018) | The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . | Abstract PDF (Eng) similar documents |
| artilce Editorial | ||
| Vol 15, No 1 (2019) | Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko | ||
| "... antagonists (warfarin) or with direct oral anticoagulants. A high risk of thromboembolic complications (CHA2DS ..." | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..." | ||
| Vol 17, No 3 (2021) | An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus | Abstract similar documents |
| V. N. Larina, O. Sh. Oynotkinova, A. P. Majorova, G. A. Egiazarian, T. Yu. Demidova | ||
| "... of the concept of comprehensive patient protection. Rivaroxaban is considered by the authors of the article ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... of antiplatelet therapy. The combination of rivaroxaban in a dose of 2.5 mg and standard double antiplatelet ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... of rivaroxaban, which create the possibility of its single administration, the evidence base for reducing ..." | ||
| Vol 10, No 2 (2014) | RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL | Abstract similar documents |
| J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson | ||
| "... Цель. Представлен анализ лечения ривароксабаном в заранее определенной подгруппе больных инфарктом ..." | ||
| Vol 11, No 5 (2015) | New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation | Abstract similar documents |
| article Editorial | ||
| "... rivaroxaban in patients with non-valvular atrial fibrillation ..." | ||
| 1 - 100 of 195 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
